Date: 2014-09-03
Type of information: Nomination
Compound: chief medical officer
Company: Kiadis Pharma (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 3, 2014, Kiadis Pharma announced the appointment of Dr. Jeroen Rovers, MD PhD, as its Chief Medical Officer. Jeroen Rovers was most recently Chief Medical Officer at Ceronco Biosciences. Prior to that he was VP Medical Affairs at Kiadis Pharma and has remained a consultant to the Company until his re-appointment on September 1, 2014. Jeroen worked at Organon (acquired by Schering – Plough in 2007) between 2005-2008, latterly as Director of Clinical Development and Business Development. Jeroen has more than 15 years of professional experience in clinical development within academia and the pharmaceutical industry. He has a strong background in cell based therapeutics/advanced-therapy medicinal products (ATMPs) and has a wealth of experience in oncology, hematology and other immunology-related fields such as organ transplantation. Jeroen has significant experience in conducting clinical trials in various oncology indications covering all phases of the clinical development pathway (Phase I to III), having coordinated clinical trials in the EU for various pharmaceutical companies. He has also been involved in early and later stage development of cancer immune therapies and conducted his doctoral thesis on the use of light-activated drugs in the treatment of tumors.
Financial terms:
Latest news:
Is general: Yes
